Clearmind Medicine Inc. Retains Edge Communications Group for Investor Relations and Announces Granting of Stock Options

Clearmind Medicine Inc.保留Edge Communications Group负责投资者关系,并宣布授予股票期权

2021-07-20 22:00:55 CFN Media Group


Toronto, Ontario– – Clearmind Medicine Inc. , a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that it has retained Edge Growth Holdings Corporation for strategic investor relations and capital markets communications services . Clearmind CEO Gadi Levin stated, “We have been following Edge closely and have been consistently impressed by their innovation in the investor relations space. We feel that our company story will resonate particularly well with their target demographic, and we are excited to begin a professional relationship that we feel will benefit our shareholders.” Edge is a team of capital markets communications professionals with a specific focus on engaging the millennial and gen z investor demographic. Edge will provide Clearmind a full spectrum communications strategy that combines traditional investor communications with new age platforms such as Instagram, TikTok, Discord & Reddit. Under the terms of the Agreement, Clearmind will pay Edge Communications Group a monthly fee of CAD $10,000 for ongoing strategic communication services. In addition, Kevan Matheson will receive 100,000 stock options with an exercise price of $0.84 that vest after 4 months and have a term of two years. The Agreement is for an initial term of four months. At the time of this announcement, neither Edge Communications Group, nor any of its executives have an ownership interest, directly or indirectly, in Clearmind or its securities. Additionally, the Company wishes to announce that in accordance with the terms of the Company’s stock option plan it has granted a total of 800,000 options (the “Options“), with an exercise price of $0.84, of which 600,000 options were issued to directors and officers and the remainder, 200,000 options, to consultants of the Company. The Options shall vest in twelve (12) equal quarterly installments over a 36-month period, with one twelfth of the Options vesting at the end of each quarter with the first vesting on October 1st, 2021. About Clearmind Medicine Inc. Clearmind is a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic derived therapeutics to solve widespread and under-served health problems including alcohol use disorder. Its primary objective is to research and develop compounds derived from psychedelics and attempt to commercialize them as regulated medicines, foods or supplements. The Company’s intellectual portfolio currently consists of two patent families, one for binge behavior regulators and the other for an alcoholic beverage substitute. Within these two families the Company has two U.S. patents, one European patent, and allowed applications in China and India and pending divisional applications in Europe and the US related to binge behavior regulators; and a European patent and pending applications in the US, China and India related to the alcohol beverage substitute family. For further information, please contact: Investor Relations Contact Email: [email protected] Telephone: (778) 400-5347 For other inquiries [email protected] FORWARD-LOOKING STATEMENTS: This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. Investing into early stage companies inherently carries a high degree of risk and investment into securities of the Company shall be considered highly speculative. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
安大略省多伦多-(Newsfile Corp.-2021年7月2日)-Clearmind Medicine Inc.(CSE:CMND)(“Clearmind”或“公司”),一家迷幻药生物技术公司,专注于发现和开发新颖的迷幻药衍生疗法,以解决广泛和服务不足的健康问题,今天宣布保留Edge Growth Holdings Corporation(“Edge Communications Group”或“Edge”)为战略投资者关系和资本市场通信服务(“协议”)。 Clearmind首席执行官Gadi Levin表示:“我们一直在密切关注Edge,并一直对他们在投资者关系领域的创新印象深刻。我们认为,我们的公司故事将与他们的目标人群产生特别好的共鸣,我们很高兴开始一种我们认为将有利于我们股东的专业关系。“ Edge是一支由资本市场沟通专业人士组成的团队,专门致力于吸引千禧一代和z世代投资者。Edge将为Clearmind提供一个全频谱的沟通策略,将传统的投资者沟通与Instagram、TikTok、Discord和Reddit等新时代平台相结合。 根据协议条款,Clearmind将向Edge Communications Group支付每月10,000加元的费用,用于持续的战略通信服务。此外,Kevan Matheson将获得10万份股票期权,行权价为0.84美元,在4个月后归属,期限为两年。该协议最初为期四个月。于本公告发表时,Edge Communications Group及其任何行政人员均无直接或间接拥有Clearmind或其证券的所有权权益。 此外,本公司谨此宣布,根据本公司股票购股权计划的条款,其已授出合共800,000份购股权(“购股权”),行使价为0.84美元,其中600,000份购股权已向本公司董事及高级人员发出,其余200,000份购股权则向本公司顾问发出。购股权将于36个月期间分十二(12)期等额季度分期付款归属,其中十二分之一的购股权于每季度末归属,第一次归属于2021年10月1日。 关于Clearmind Medicine Inc. Clearmind是一家迷幻药生物技术公司,专注于发现和开发新的迷幻衍生疗法,以解决广泛和服务不足的健康问题,包括酒精使用障碍。它的主要目标是研究和开发从迷幻药中提取的化合物,并试图将它们作为受管制的药物、食品或补充剂商业化。 该公司的知识组合目前由两个专利家族组成,一个是狂饮行为调节器,另一个是酒精饮料替代品。在这两个家族中,该公司拥有两项美国专利、一项欧洲专利,并在中印获得了许可申请,在欧洲和美国获得了与狂欢行为监管机构有关的待审部门申请;和一项欧洲专利,并在美国、中印等国申请与酒精饮料替代品有关。 如需进一步资料,请联络: 投资者关系联络 电子邮件:[email protected] 电话:(778)400-5347 其他查询 [电子邮件受保护] 前瞻性陈述: 本新闻稿可能包含基于当前预期的前瞻性陈述和信息。这些声明不应被理解为对未来业绩或结果的保证。此类陈述涉及已知和未知的风险、不确定性和其他因素,可能导致实际结果、业绩或成就与此类陈述所暗示的结果、业绩或成就大不相同。这些声明包括在规定的时间内提交相关文件,使相关监管机构满意,并筹集足够的资金来完成公司的业务战略。这些事件中的任何一个都不确定会发生。尽管该等陈述是基于管理层的合理假设,但不能保证该等假设将被证明是正确的。我们不承担更新或修改它们以反映新的事件或情况的责任。 投资于早期公司本身具有很高的风险,投资于该公司的证券应被视为高度投机性。 本新闻稿不构成出售要约或邀请购买要约,也不构成在任何要约、邀请或出售为非法的省份出售证券。根据私募发行已发行或将发行的证券并无且将不会根据经修订的1933年美国证券法进行登记,且如无登记或登记规定的适用豁免,不得在美国发售或出售。 加拿大证券交易所及其监管服务提供商(CSE的政策中定义了该术语)都不对本新闻稿的充分性或准确性承担责任。 本文由CFN Enterprises Inc.(OTCQB:CNFN)发表,该公司是CFN Media的所有者和运营商,CFN Media是行业领先的机构和数字金融媒体网络,致力于新兴的CBD和合法大麻行业。请致电+1(833)420-CNFN了解更多信息。